Hosted on MSN23h
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
Argenx upgraded at Wolfe on myasthenia gravis dominance
Argenx (ARGX) stock upgraded at Wolfe Research citing dominance in myasthenia gravis market and profitability outlook. Read ...
Argenx and Zai Lab’s CIDP Drug Approved in China
Argenx Se (ARGX) has released an update. Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval ...
Argenx, Zai Lab announce approval of VYVGART Hytrulo in China
(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...
Business Wire2d
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...